SUMMARY Thirty-three children aged between 1 month and 16 years (median 1 year, 7 months), were treated for stage II neuroblastoma with surgery, radiotherapy, or chemotherapy, alone or in combination. After 3 years 70 % were living, 6 children had died from the disease, and 4 had died as a result of treatment. Patient characteristics (age, gender) and tumour characteristics (primary site, presence of lymph node involvement, catecholamine excretion, histology) were reviewed in an attempt to determine prognostic features. While age under 1 year at diagnosis was, as expected, favourable in this series, the most important prognostic variable was the presence or absence of regional lymph node involvement. No patient with uninvolved nodes died of neuroblastoma and the difference in the 3-year survival rate between these patients and those with positive nodes was statistically significant. Although this study of patients treated between 1970 and 1977 provided no clear evidence that either postoperative radiotherapy or contemporary chemotherapy was of benefit, our findings suggest that subclassification of stage II patients into ' node-positive ' and ' nodenegative' groups will help to define those who might benefit from improved adjuvant postsurgical treatment.
treatment.
According to the clinical staging system of Evans et 
Results
Of the 33 children, 23 are alive and free of disease between 42 and 129 (median 79) months after diagnosis, giving an overall survival of 70 % (Fig. 1) .
Six patients died from tumour between 2 and 26 months after diagnosis; their clinical courses are shown in Table 1 . Four deaths were caused by treatment, 2 in the immediate postoperative period and 2 at a later date from adriamycin cardiomyopathy with no evidence of tumour. Of the last 2 patients, the first was a 6-year-old girl with an unresectable mediastinal tumour. She was treated with radiotherapy (2000 cGy in 10 fractions over 14 days) and chemotherapy. She died one year after start of treatment. At that time she had been given a total dose of 680 mg/M2 adriamycin. The second child was a 9-year-old boy who had a partial resection of a mediastinal 'dumb-bell' neuroblastoma. He was also treated with radiotherapy (3500 cGy in 18 fractions over 28 days) and chemotherapy. He died 9 months later after having received 520 mg/M2 adriamycin.
Prognostic features ( Table 2 , Fig. 1 ).
Lymph node invasion
While 4 of the 20 patients without lymph node involvement died of treatment-related complications, none died of neuroblastoma (Fig. 2) . By contrast, 6 of the 13 node-positive patients-and all involved nodes were, by definition, homolateral-subsequently died of recurrent or metastatic tumour. This difference in survival was statistically significant (P<0.01).
Age
As expected, children under age 1 year at diagnosis fared better (P<0. 05) than older patients; all tumour-related deaths were in the latter group.
Histology
No patient with ganglioneuroblastoma died from tumour but the difference in survival between these children and those with neuroblastoma was not statistically significant.
Other features
The gender of the patient, presence or absence of VMA excretion, and site of primary tumour were of no prognostic significance. Treatment (Table 3) . Patients dying of treatment complications were excluded from our analysis of the influence of treatment on tumour-related survival.
Surgery
Three-year survival after partial resection (88 %) was as good as after complete resection (81 %). Since the proportion of patients in the two groups receiving postoperative radiotherapy or chemotherapy was similar (Table 3) , this effect was not The most important single prognostic feature in our series was the presence of positive homolateral lymph nodes at diagnosis. While no patient without node involvement died from neuroblastoma, the survival rate of node-positive patients was only 0 -54 %. Although the adverse prognostic significance of regional lymph node involvement in patients with localised Wilms's tumour has been appreciated for a number of years,7 8 few analyses have focused on the possible importance of regional node involvement in localised neuroblastoma. However, the conclusion of a recent study at St Jude Hospital, published in abstract form,9 was similar to our own. The possible reasons for less favourable survival in node-positive patients include a biologically more aggressive type of tumour or some failure of host-defence mechanisms in these children.
Age at diagnosis was another feature of prognostic value; our results are thus at variance with a recent report claiming that the effect of age appears insignificant in a small series of patients with localised thoracic tumours.10 On the contrary, we agree with others that stage and age are independent variables and that children aged under 1 year at diagnosis fare better than older children.2 61112 A third variable of prognostic value in this series was histology; patients with localised ganglioneuroblastoma fared better than those with neuroblastoma but the difference was not statistically significant (Table 2 ). Increased maturation of localised neuroblastoma has also been related to more favourable prognosis in two recent studies.13 14 Other variables-such as gender, site of primary, and VMA secretion-were of no prognostic value. A high ratio of VMA to homovanillic acid (HVA) excretion seems to correlate with a better prognosis than the inverse ratio.15 Since HVA estimation was not available during the 1970-77 period we were unable to analyse the prognostic value of the VMA/ HVA ratio in our patients.
Except in one small subgroup of patients, postoperative chemotherapy or radiotherapy did not improve disease-free survival compared with surgery alone (Table 3 ). Only patients with lymph node involvement fared somewhat better if they were treated with chemotherapy. Although the difference was not statistically significant, chemotherapy regimens were, by present-day standards, often 'gentle' in these patients. These data confirm the results of similar studies of treatment for localised neuroblastoma; there is no evidence to support the notion that patients treated with postoperative radiotherapy or single agent chemotherapy or both have a better survival rate than those who undergo surgery alone.4610 In the only report claiming 100% 2-year disease-free survival for 11 children treated with radiotherapy or chemotherapy after resection of a localised mediastinal neuroblastoma, there was no control group treated by surgery alone for com-
parison.16
The risks of adriamycin treatment after thoracic radiation are now better appreciated than in the 1970-77 period and the 2 adriamycin/radiationrelated deaths would probably not now occur. In addition, it has been shown,17 and recently confirmed by us,18 that adriamycin does not improve the survival rate in patients with advanced (stages III and IV) neuroblastoma when added to pulsed cyclophosphamide-vincristine-DTIC or to pulsed cyclophosphamide-vincristine. Thus, although adriamycin cardiomyopathy can be detected early by regular radionuclide assessment of left ventricular ejection fraction19 and its incidence much reduced by limiting the total cumulative dose to 400 mg/M2 when the myocardium has been irradiated,20 this drug cannot be recommended for patients with localised disease.
We conclude that surgery alone seems to be adequate treatment for patients with stage II neuroblastoma without lymph node involvement. Patients with positive regional (homolateral) nodes, on the other hand, comprise a group at increased risk of developing recurrent or metastatic disease which should, we believe, be distinguished from the node-negative group in any staging system used.
is more widely accepted we suggest the use of a modification to the familiar Evans' 
